dalfampridine

Acorda Therapeutics Inc (NASDAQ: ACOR) accused one of its rivals, Par Pharmaceutical, of infringing patents related to its multiple sclerosis treatment drug called Ampyra (dalfampridine) back in September, 2015. Par Pharmaceutical was seeking marketing approval from the FDA for its generic...

Shares of Acorda Therapeutics, Inc. (Nasdaq: ACOR) are trading up 8.8% at $30.09 per share during the Monday afternoon trading session. The company announced on Monday morning that its AMPYRA (dalfampridine) Extended Release Tablets, reached 4th quarter sales of $55.7 million and that its Zanaflex...